| Related Articles |
Biologic and New Therapies in Asthma.
Immunol Allergy Clin North Am. 2017 May;37(2):329-343
Authors: Tabatabaian F, Ledford DK, Casale TB
Abstract
Several biologics are currently FDA approved for asthma that target Th2 high patients. Unfortunately, 50% of patients with severe asthma do not fit this phenotype of disease and have fewer effective therapeutic options. In the clinical setting, total IgE, FeNO and peripheral blood eosinophils are important tools in defining Th2 high patients with asthma. However, precise biomarkers to predict better response to one specific Th2 high asthma therapy versus another is lacking. It is important to recognize that none of the current medications targeting the Th2 pathway induces persistent immunomodulation or remission.
PMID: 28366480 [PubMed - in process]
http://ift.tt/2oGxGEe
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου